Tradr 2X Long TEMT Daily ETF (TEMT) is a small, single-stock leveraged fund that seeks twice the daily percentage performance of Tempus AI (TEM) common stock, the Chicago-based precision-medicine and healthcare data company. The ETF moves only as fast as its underlying, and on Monday that underlying moved sharply lower. TEMT traded at $22.45, down 15.06% from Friday's $26.43 close, a decline of $3.98. The move was confirmed as a decline, not a bounce. Markets cited no new fund or issuer news; the driver was the underlying stock's slide of roughly 7.3%, doubled by the fund's daily leverage and compounded by the fixed-cost drag built into daily-reset leveraged products.
TEMT does not pick its own direction. Its mandate is a 200% daily exposure to Tempus AI, reset each session, which means a 7% move in the underlying translates into roughly a 14% move in the fund before fees and compounding effects. Monday's session delivered exactly that math: Tempus AI fell to about $66.39 from $71.60, and the ETF's 15.06% decline tracked closely with the doubled daily return. Because the fund resets daily, volatile stretches in the underlying erode net asset value faster than a simple two-times multiple would suggest, and the vehicle's net assets of roughly $35 million make it sensitive to order flow.
The broader catalyst was a rotation away from speculative, high-multiple AI and genomics names. Tempus AI carries a beta of about 3.6, making it one of the more rate-sensitive growth equities in healthcare, and Monday's tape featured firming Treasury yields, pressure across AI-adjacent equities and caution ahead of Nvidia's results on Tuesday. Peer diagnostics and genomics names traded broadly lower as well, so the move was sector-wide rather than idiosyncratic. Market participants also pointed to the possibility that investors are liquidating existing technology positions to fund participation in anticipated AI-related new issues, a dynamic that disproportionately hits crowded, high-beta holdings.
Tempus AI's third-quarter report on Nov. 2 was strong: revenue of $411.5 million rose 23% year over year, adjusted EBITDA reached $25.6 million, and management raised its 2026 revenue outlook to $1.60 billion to $1.605 billion. The stock rallied hard on those numbers, and Jefferies subsequently lifted its rating to Hold from Underperform with a $70 price target. Monday's action was the third consecutive lower session and followed a 5.7% drop on Friday, consistent with profit-taking in a stock still sitting well below its September high. The company also continues to await shareholder approval of its pending Personalis acquisition, with a vote scheduled for Nov. 30.
Volume was not elevated. Roughly 25,000 TEMT shares traded by early afternoon against a typical full-session average in the 175,000 to 270,000 range, indicating that the decline was driven by a thin order book rather than heavy institutional distribution. The move was aligned with the underlying and with broader weakness in genomics and diagnostics peers, while the major indices themselves were far more contained, underlining that this was a high-beta, single-name event rather than a market-wide selloff. Technically, the fund broke below its 20-day moving average and lost the $24 area that had acted as support late last week, with the next reference points the mid-November low near $22.12 and, above the market, the $26 to $27 zone.
The score runs from 0, meaning no meaningful news and a price move that is normal for the instrument, to 100, meaning transformative news and an extreme, rare move. This event scores 18 out of 100. The verified news was weak: there was no issuer disclosure, no filing and no analyst action specific to the fund, only a sector- and macro-driven decline in the underlying stock that was already in progress. The price move was also unremarkable by this instrument's standards. At 15.06%, it was about 1.8 times the typical 8.4% absolute daily move, and 11 of the last 60 sessions produced moves of equal or larger size. With both components weak, the result is a low score.
Attention now shifts to the underlying company's news flow. Tempus AI has no scheduled earnings release before its fourth-quarter report, but the Nov. 30 Personalis shareholder vote is a defined event that could move the stock, and any update on the Bristol Myers Squibb and Moderna/Merck collaborations would matter. On the macro side, Nvidia's results on Tuesday and the path of Treasury yields will shape appetite for high-beta AI exposure. Analyst sentiment remains constructive, with a consensus leaning toward Buy, though the Jefferies target near $70 sits close to the current price. Risks include further multiple compression in unprofitable growth names, integration risk around the pending acquisition, and the structural drag that daily rebalancing imposes on leveraged funds during choppy markets.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the page offers a practical way to compare approaches side by side. For traders navigating a fast-moving, leveraged instrument like this one, reviewing which strategies are currently working can sharpen execution and risk discipline. Explore the page to see which bots are leading right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for TEMT crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +41.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEMT advanced for three days, in 76 of 80 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 15 of 16 cases where TEMT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEMT as a result. In 22 of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TEMT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 12 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TEMT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TEMT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TEMT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.